14.51

3.97% -0.60

After Hours: 14.51

Enanta Pharmaceuticals Inc (ENTA)

Overview News Price History Option Chain Financials Discussions Forecast

Enanta Pharmaceuticals Inc stock is traded at $14.51, with a volume of 204.96K. It is down -3.97% in the last 24 hours and up +28.63% over the past month. Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Previous Close:

$15.11

Open:

$14.9

24h Volume:

204.96K

Relative Volume:

1.05

Market Cap:

$421.93M

Revenue:

$69.21M

Net Income/Loss:

$-61.98M

P/E Ratio:

-5.5922

EPS:

-2.5947

Net Cash Flow:

$-9.61M

1W Performance:

+0.00%

1M Performance:

+28.63%

6M Performance:

+6.85%

1Y Performance:

+83.90%

1-Day Range:

$14.41

$15.10

1-Week Range:

$14.26

$15.51

52-Week Range:

$6.435

$17.15

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name

Enanta Pharmaceuticals Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

617 607 0800

Address

4 KINGSBURY AVENUE, WATERTOWN, MA

Employee

120

Twitter

@EnantaPharma

Next Earnings Date

2026-08-10

Latest SEC Filings

ENTA's Discussions on Twitter

Compare ENTA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENTA Enanta Pharmaceuticals Inc	14.51	423.96M	69.21M	-61.98M	-9.61M	-2.5947
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-26-26	Initiated	Rodman & Renshaw	Buy
Nov-14-25	Initiated	JP Morgan	Overweight
Oct-01-25	Upgrade	Jefferies	Hold → Buy
Jul-28-25	Resumed	H.C. Wainwright	Buy
Aug-09-23	Downgrade	JP Morgan	Neutral → Underweight
Aug-08-23	Downgrade	Jefferies	Buy → Hold
Dec-09-22	Initiated	H.C. Wainwright	Buy
Jul-06-22	Upgrade	Evercore ISI	In-line → Outperform
Jun-01-22	Upgrade	Evercore ISI	Underperform → In-line
Oct-07-21	Initiated	Jefferies	Buy
Sep-09-21	Initiated	SVB Leerink	Mkt Perform
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral
Nov-24-20	Initiated	Evercore ISI	Underperform
Aug-28-20	Resumed	ROTH Capital	Buy
Aug-26-20	Initiated	Piper Sandler	Overweight
Jul-27-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Mar-17-20	Upgrade	Robert W. Baird	Neutral → Outperform
Nov-22-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-26-19	Downgrade	JP Morgan	Neutral → Underweight
May-24-19	Initiated	Wolfe Research	Outperform
Apr-23-19	Upgrade	Berenberg	Hold → Buy
Dec-13-18	Initiated	Berenberg	Hold
Jun-06-18	Initiated	ROTH Capital	Buy
Feb-08-18	Downgrade	JP Morgan	Overweight → Neutral
Jan-02-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-21-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Jul-11-17	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Apr-28-16	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-09-16	Reiterated	Barclays	Underweight
Oct-23-15	Downgrade	Barclays	Equal Weight → Underweight
Oct-23-15	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform

View All

Enanta Pharmaceuticals Inc Stock (ENTA) Latest News

Jul 02, 2026

Federal Circuit Rules Written Description Standard Governs Patent Priority In Enanta Pharmaceuticals v. Pfizer (PFE) - londoninsider.co.uk

Jul 02, 2026

Jul 01, 2026

Price to sales forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView

Jul 01, 2026

Jun 29, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Vance Terry - Moomoo

Jun 28, 2026

Enanta Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo

Jun 28, 2026

Jun 27, 2026

AbbVie, Enanta announce EU label expansion for hepatitis C therapy, Maviret - MSN

Jun 27, 2026

Enanta Pharmaceuticals (ENTA) moves 5.2% higher: Will this strength last? - MSN

Jun 27, 2026

Jun 26, 2026

Enanta Pharmaceuticals sets out pipeline catalysts, shares watched by biotech investors - AD HOC NEWS

Jun 26, 2026

Enanta Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ENTA) - TradingView

Jun 26, 2026

Jun 25, 2026

Pfizer patent win against Enanta over COVID pill upheld by appeals court - MSN

Jun 25, 2026

Price to book forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView

Jun 25, 2026

Price to earnings forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView

Jun 25, 2026

Enterprise value to revenue forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView

Jun 25, 2026

Price to book forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView

Jun 25, 2026

ENTA Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

PATENT—Fed. Cir.: Pfizer Inc. prevails in coronavirus-treatment patent dispute with biotechnology company - VitalLaw.com

Jun 24, 2026

Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance

Jun 24, 2026

EC approves label expansion for Enanta’s Maviret in acute HCV infection - The Pharma Letter

Jun 24, 2026

Form 8K Enanta Pharmaceuticals Inc For: 23 June - Investing.com UK

Jun 24, 2026

Jun 23, 2026

Federal appeals court upholds invalidity of Enanta patent in Pfizer case By Investing.com - Investing.com South Africa

Jun 23, 2026

Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com South Africa

Jun 23, 2026

Federal appeals court upholds invalidity of Enanta patent in Pfizer case - Investing.com UK

Jun 23, 2026

H.C. Wainwright reiterates Enanta stock rating on FDA alignment - Investing.com UK

Jun 23, 2026

Enanta Faces Patent Setback in Paxlovid Litigation - TipRanks

Jun 23, 2026

H.C. Wainwright reiterates Enanta stock rating on FDA alignment By Investing.com - Investing.com South Africa

Jun 23, 2026

[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event - Stock Titan

Jun 23, 2026

CAFC Affirms Enanta Coronavirus Patent Invalid for Lack of Written Description Support in Provisional Application - IPWatchdog.com

Jun 23, 2026

Pfizer Keeps Win in Patent Lawsuit Aimed at Paxlovid Antiviral - Bloomberg Law News

Jun 23, 2026

Enanta (ENTA) Secures EU Approval for Maviret Treatment - GuruFocus

Jun 23, 2026

ENTA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus

Jun 23, 2026

Enanta Pharmaceuticals? Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - marketscreener.com

Jun 23, 2026

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - BioSpace

Jun 23, 2026

H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20 - Moomoo

Jun 23, 2026

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET - Business Wire

Jun 23, 2026

Jun 22, 2026